BioCentury's latest biopharma roundup includes approvals for Ultragenyx, Epizyme, Merck; plus a Tecfidera tussle, Tecentriq wins again in TNBC, Sarepta-Selecta, &amp; Gelesis goes to China $RARE $BIIB $RHHBY $MYL $EPZM $SELB $SRPT $MRK $PRTC https://t.co/J0yYC5GN1C